InvestorsObserver
Sign Up Login

XBI SPDR Biotech ETF

$83.49 $1.27 (1.54%)
15 Minute Delayed Price Enable Real-Time Price
Add to Watchlist Compare
Overall

XBI Stock Analysis Overview

What this means: InvestorsObserver gives SPDR Biotech ETF (XBI) an overall rank of 31, which is below average. SPDR Biotech ETF is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 31 means that 69% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

XBI Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

XBI Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

XBI Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

XBI Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

XBI Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

XBI Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

XBI Stock Analysis Overview

What this means: InvestorsObserver gives SPDR Biotech ETF (XBI) an overall rank of 31, which is below average. SPDR Biotech ETF is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 31 means that 69% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full XBI report

XBI Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

XBI Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

XBI Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

XBI Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

XBI Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

XBI Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

SPDR Biotech ETF (XBI) Analyst Forecast

XBI Price, Volume, Earnings, and Dividend Date

  • Last Price $83.49
  • Previous Close $82.22
  • Change $1.27
  • Open $82.58
  • Volume 10,390,133
  • Avg. Volume (100-day) 11,617,470
  • Market Cap 6,513,889,800
  • Days Range 81.63 - 83.87
  • 52-week Range 63.8 - 103.52
  • Dividend Yield 0.04%
  • Ex. Dividend Date 12/18/23
  • P-E 22.67
  • EPS —
  • Earnings Date —
  • Sector —
  • Industry —
  • Avg. Analyst Rec. Premium
  • Beta 1.645
  • PEG Ratio —

SPDR Biotech ETF (XBI) Company Description

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the index), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index (S&P TMI).

SPDR Biotech ETF (XBI) Stock Chart

View Interactive XBI chart

My Watchlists

Top Stocks